SGMO

Price & events

Pipeline stages · 3 programs

Pipeline · 3 trials · 1 upcoming

Catalyst news & presentations · 13

• 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
• 2026-06-24withdrawalCommon stock began trading on OTCID Basic Market under symbol SGMOQ after Chapter 11 filingSEC 8-K
• 2026-05-05withdrawalCommon stock suspended from trading on Nasdaq and began trading on OTCQBSEC 8-K
• 2026-04-28withdrawalNasdaq determined to delist common stock due to non-compliance with minimum bid priceSEC 8-K
• as early as the first quarter of 2026regulatory submissionFiled (NDA/BLA)isaralgagene civaparvovec · BLA submission under Accelerated Approval pathwaySEC 8-K
• February 2-6, 2026conferencedata presentationsecondaryPhase 1/2isaralgagene civaparvovec · Presented Phase 1/2 STAAR study data at WORLD SymposiumSEC 8-K
• second half of 2025regulatory submissionFiled (NDA/BLA)ST-920 · BLA submission anticipatedSEC 8-K
• December 2025regulatory submissionFiled (NDA/BLA)isaralgagene civaparvovec · Initiated rolling BLA submission for accelerated approvalSEC 8-K
• 2025-10-31fda agreementisaralgagene civaparvovec · FDA agreed Phase 1/2 data can serve as primary basis for accelerated approval using eGFR slopeSEC 8-K
• first half of 2025readoutPhase 1/2ST-920 · 52-week eGFR slope data expectedSEC 8-K
• December 9, 2024conferencedata presentationsecondaryPhase 3giroctocogene fitelparvovec · Pfizer presented detailed Phase 3 AFFINE trial data at the 66th ASH Annual Meeting.SEC 8-K
• 2024-10-01fda agreementisaralgagene civaparvovec (ST-920) · FDA agreed eGFR slope at 52 weeks as intermediate endpoint for Accelerated ApprovalSEC 8-K
• July 24, 2024readoutPhase 3giroctocogene fitelparvovec · Positive topline results from registrational Phase 3 AFFINE trialSEC 8-K